

THE UNIVERSITY OF MANITOBA

SEARCH FOR ABNORMALLY SYNTHESIZED PROTEINS IN NERVOUS
TISSUES OF HAMSTERS AND MICE
WITH GENETICALLY DETERMINED MUSCULAR DYSTROPHY

by

Marilyn D. Hayward


A THESIS

SUBMITTED TO THE FACULTY OF GRADUATE STUDIES
IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE
OF MASTERS OF SCIENCE

DEPARTMENT: BIOCHEMISTRY

WINNIPEG, MANITOBA

OCTOBER 1979



SEARCH FOR ABNORMALLY SYNTHESIZED PROTEINS IN NERVOUS
TISSUES OF HAMSTERS AND MICE
WITH GENETICALLY DETERMINED MUSCULAR DYSTROPHY

BY

MARILYN DOROTHY HAYWARD

A thesis submitted to the Faculty of Graduate Studies of
the University of Manitoba in partial fulfillment of the requirements
of the degree of

MASTER OF SCIENCE

©1980

Permission has been granted to the LIBRARY OF THE UNIVER-
SITY OF MANITOBA to lend or sell copies of this thesis, to
the NATIONAL LIBRARY OF CANADA to microfilm this
thesis and to lend or sell copies of the film, and UNIVERSITY
MICROFILMS to publish an abstract of this thesis.

The author reserves other publication rights, and neither the
thesis nor extensive extracts from it may be printed or other-
wise reproduced without the author's written permission.

For my friend and husband Rolly

with love-

"...let truth be free to make her sallies upon Thee,
and Me, which way it pleases God. For who knows how,
better than he that taught us first to plough, to
guide our mind and pens for his design? And He makes
base things usher in Divine...."

-John Bunyan, Pilgrims Progress

ACKNOWLEDGMENTS

I would like to thank Dr. Klaus Wrogemann for his help and endurance in having me complete my work and my thesis in his laboratory. To Dr. M.C. Blanchaer I give my gratitude for his guidance and support in undertaking this work and experiencing science dynamically.

I would like to acknowledge the Muscular Dystrophy Association of Canada for providing the funding and giving me the opportunity to do this work.

Most importantly I thank my family for their love and support through the years of studying at university. It took their sacrifice and strength of mind and heart to help me come to this day. To Mr. and Mrs. R.B. Hayward I also give my thanks, both for their friendship and sense of duty and for their home which they shared with me while I completed my thesis.

ABSTRACT

Muscular dystrophy is a group of genetically determined diseases characterized by muscular weakness and wasting. As in other inborn errors of metabolism the genetic defect(s) in the muscular dystrophies appear to be expressed in many tissues besides muscle and heart. Assuming that the genetic defect is expressed in(an) altered protein(s) a systematic search was performed for abnormally synthesized proteins in nervous tissues of two animal models of muscular dystrophy, the genetically determined muscular dystrophies in hamster, strain BIO 14.6 and mice, strain 129Rej/dydy.

To investigate the metabolism of the two different animals(diseased and control) simultaneously and to ensure exact reproducibility between the fractionation of diseased and control animal tissues a dual labelling technique was employed. Radioisotopes of leucine, L-(U¹⁴C)leucine and L-(4,5³H)leucine, were injected intraperitoneally into age-matched pairs of dystrophic and normal animals respectively. After a set period of incubation with the radioisotope the animals were killed and tissues were excised, combined into one preparation for homogenization and subcellularly fractionated. The dual labelling technique used in this way allows the comparison of the in vivo incorporation of ³H and ¹⁴C-leucine into various protein fractions in the normal and dystrophic animals. Proteins were separated by three analytical methods: SDS gel electrophoresis, disc gel electrophoresis and isoelectricfocusing.

A study of brain subcellular fractions of Syrian hamsters(1-6-days-old) by SDS gel electrophoresis and isoelectricfocusing showed no detectable difference between normal and dystrophic hamsters. An apparent abnormality of the particulate fractions was found to be an artifact of the leucine labels and could be removed by acetone extraction.

The dual labelling technique was used to investigate known neural abnormalities of the murine dystrophy. Preliminary work with the brain soluble and particulate fractions(mitochondrial) indicated no detectable abnormality was present in the dystrophic mice(4-12-weeks-old). Extirpated spinal cord homogenates of these mice showed protein abnormalities.

Dystrophic mice which were 29-days-old showed a decreased label incorporation into protein fractions in a region of an approximate molecular weight of 23,000. This may have been a true abnormality ultimately caused by the dystrophic gene. Lubrol solubilized homogenates of the spinal cord fractionated on isoelectricfocusing gels indicated two abnormalities in dystrophic mice of both 47 and 66 days of age. SDS gels of unlabelled spinal cord, spinal roots and sciatic nerve gave reproducible differences between 129Rej/dydy and 129Rej/?? mice; the dystrophic mice showing a decreased quantity of several protein components of high and low molecular weights. Using the 4.5% polyacrylamide gel with SDS but a Tris-EDTA buffer system spinal cord homogenates showed several components altered in concentration in the dystrophic mice compared to their normal littermates.

The pattern of leucine incorporation into various protein fractions of brain from both dystrophic mice and hamsters showed a remarkable identity between normal and dystrophic animals. This can be taken as conclusive evidence that there are no gross defects in any of the more abundant proteins of the brain.

Several abnormalities were detected in the spinal roots and sciatic nerve of dystrophic mice. However, the incorporation of labelled leucine into these fractions was too low to resolve the abnormalities reliably. Future studies, possibly on newborn animals and employing two-dimensional electrophoretic techniques may be required to clarify these findings.

TABLE OF CONTENTS

	Page
Acknowledgments	3
Abstract	4
Table of Contents	6
List of Abbreviations	9
List of Figures	10
List of Pictures	13
List of Tables	14
I. INTRODUCTION	15
II. HISTORICAL LITERATURE REVIEW	19
A. Muscular Dystrophy in Man and Animals.....	19
B. Evidence for Neurologic Involvement in Muscular Dystrophy.....	21
1. Muscle transplantation in the animal muscular dystrophies-the effects of normal and dystrophic innervation.....	23
2. Organ culture of muscle under the influence of dystrophic spinal cord motoneurons.....	24
3. Mouse chimaera studies-the absence of dystrophic muscle histology in the presence of dystrophic myonuclei.....	25
4. Altered enzyme activities in dystrophic muscle fibres	25
5. Altered lipid composition of muscle membranes in dystrophic animals.	28
6. Axoplasmic flow abnormalities in animals with muscular dystrophy.....	28
7. Histological abnormalities in the nervous system of animals with muscular dystrophy.....	30
8. Proteins of muscle under neural control-in denervated and dystrophic muscle	31
9. Parabiosis studies in muscular dystrophy-a controversy over a neural involvement.....	33
10. Electrophysiological studies on dystrophic muscle.	34
C. Dual Labelling: a Useful Technique to Investigate Inborn Errors of Metabolism.....	36

III. MATERIALS AND METHODS.....	38
A. Materials.....	38
1. Animal strains.....	38
2. Chemicals.....	38
B. Methods	41
1. Labelling and Dissection of Tissues	41
2. Homogenization	41
3. Differential Centrifugation	42
4. Removal of Free Leucine.....	42
5. Acetone Extraction Procedure	46
6. Analytical Techniques	47
a) Type I-SDS gels	47
b) Type II-SDS disc gels	48
c) Type III-SDS-EDTA gels	49
d) Type IV-IEF gels	49
7. Gel staining and Destaining Procedures	50
8. Assay of Radioactivity	51
9. Analysis of Data in Dual Labelling	52
IV. RESULTS AND DISCUSSION	55
A. Nervous System Protein Synthesis in BIO 14.6 Hamsters	55
1. Time Study for Optimum Incorporation of Labelled Protein Precursor	55
2. Application of the Dual Labelling Technique to Proteins of the Nervous System	55
a) Brain subcellular fractions	55
i) Brain supernatant fractions	55
ii) Brain particulate fractions	69
iii) Acetone extraction of particulate fractions	81
iv) Brain particulate fractions-isoelectric-focusing separation	87
b) Spinal Cord proteins in normal and dystrophic hamsters	87
B. Nervous System Proteins in Bar Harbour 129Rej/dydy Mice	96
1. The Dual Labelling Technique Applied to the Study of Nervous System Proteins in Dystrophic Mice	96
a) Brain subcellular fractions	96
i) Brain supernatant fractions	96
ii) Brain mitochondrial fractions.....	101

b)	Spinal cord(with spinal roots) proteins.....	101
i)	Spinal cord polypeptides separated by SDS-PAGE.....	101
ii)	Spinal cord polypeptides separated by IEF separation.....	126
2.	Spinal Cord, Sciatic Nerve and Spinal Roots Separated by SDS-PAGE.....	134
a)	Spinal cord polypeptides.....	134
i)	Separation on 13% SDS disc gels.....	134
ii)	Separation on 4.5% SDS-EDTA gels.....	137
b)	Spinal Root and Sciatic Nerve polypeptides.....	137
i)	Separation on 13% SDS disc gels.....	137
ii)	Separation on 4.5% SDS-EDTA gels.....	139
C.	Discussion.....	145
V.	CONCLUSIONS.....	147
VI.	APPENDIX.....	149
VII.	BIBLIOGRAPHY.....	154

LIST of ABBREVIATIONS

ACh.....	acetylcholine
AChE.....	acetylcholinesterase
CAT.....	choline acetyltransferase
d.....	daltons
DMD.....	Duchenne muscular dystrophy
DNA.....	deoxyribonucleic acid
EDB.....	extensor digitorum brevis muscle
EDTA.....	ethylene diamine tetraacetic acid
EGTA.....	ethylene glycol-bis(-aminoethyl ether)N,N tetraacetic acid
EDL.....	extensor digitorum longus muscle
G-6-PDH.....	glucose-6-phosphate dehydrogenase
IEF gel.....	isoelectric focusing gel
HbS.....	sickle cell hemoglobin
Leu.....	leucine
LDH.....	lactate dehydrogenase
mepps.....	miniature end plate potentials
MeV.....	million electron volts
MD.....	muscular dystrophy
MICRO.....	microsomal pellet subcellular fraction
MITO.....	mitochondrial pellet subcellular fraction
mm.....	millimetres
M.W.....	molecular weight
NADH.....	nicotinamide adenine dinucleotide
N-DNP-L-LEU.....	dinitrophenyl-L-leucine
NP.....	nuclear pellet
PA.....	polyacrylamide
PAGE.....	polyacrylamide gel electrophoresis
PM.....	picomoles
PMSF.....	phenylmethylsulfonyl fluoride
RBC.....	red blood cell
SC.....	Schwann cell(s)
SD.....	standard deviation
SDH.....	succinate dehydrogenase
SDS.....	sodium dodecyl sulfate
SOL.....	soleus muscle
spec. act.....	specific activity
SR.....	sarcoplasmic reticulum
SUP.....	ultrasupernatant fraction, supernatant
T.D.....	tracking dye
TEMED.....	N,N,N',N'-tetramethylethylene diamine
uF.....	microfarad
ul.....	microlitre

LIST OF FIGURES

FIGURE

1.	Flow scheme of the double labelling technique	17
2.	Differential centrifugation procedure for obtaining subcellular fractions of brain	43
3.	G-25 Sephadex column elution profile	45
4.	Time study for ^3H -leucine incorporation into tissues of newborn hamsters	
	a) profile of brain and skeletal muscle supernatant fractions	57
	b) profile of kidney, heart, and liver supernatant fractions	58
5.	10% SDS gel (Type I) of double-labelled brain supernatants of two age-matched (3-day-old) RB hamsters; picomole plot and ratio of $^{14}\text{C}/^3\text{H}$ leucine incorporation	61
6.	10% SDS gel of double-labelled brain supernatants of two age-matched (3-day-old) RB hamsters; % picomole plot and normalized ratio of $^{14}\text{C}/^3\text{H}$ leucine incorporation	63
7.	10% SDS gel of double-labelled brain supernatant of RB (1-day-old) and BIO 14.6 (2-day-old) hamsters	66
8.	10% SDS gel of double-labelled brain supernatant of RB (1-day-old) and BIO 14.6 (1-day-old) hamsters	68
9.	10% SDS disc gel of double-labelled brain supernatant of age-matched (6-day-old) RB and BIO 14.6 hamsters	71
10.	5.1% IEF gel pH gradient from pH 3.5-10.0 of double-labelled brain supernatant of age-matched (6-day-old) RB and BIO 14.6 hamsters	73
11.	10% SDS disc gel (Type II) of double-labelled brain nuclear pellet fraction of age-matched (6-day-old) RB and BIO 14.6 hamsters	76
12.	10% SDS disc gel of double-labelled brain mitochondrial fraction of age-matched (6-day-old) RB and BIO 14.6 hamsters	78
13.	10% SDS disc gel of double-labelled brain mitochondrial fraction from a single (3-day-old) RB hamster	80
14.	10% SDS disc gels of double-labelled brain nuclear pellet fractions of a single RB hamster before and after acetone extraction	83
15.	10% SDS disc gels of double-labelled brain nuclear pellet fractions of age-matched (6-day-old) RB and BIO 14.6 hamsters before and after acetone extraction	85
16.	5.1% IEF gel pH gradient from pH 3.5-10.0 of double-labelled brain nuclear pellet fraction of age-matched (6-day-old) RB and BIO 14.6 hamsters	89

FIGURE

17.	5.1% IEF gel pH gradient from pH 3.5-10.0 of double-labelled brain mitochondrial fraction of age-matched(6-day-old) RB and BIO 14.6 hamsters	91
18.	13% SDS disc gel of double-labelled spinal cord homogenates of age-matched(30-day-old) RB and BIO 14.6 hamsters-SDS soluble fraction (¹⁴ C in BIO 14.6 hamster)	93
19.	13% SDS disc gel of double-labelled spinal cord homogenates of age-matched(30-day-old) RB and BIO 14.6 hamsters-SDS soluble fraction (¹⁴ C in RB hamster)	95
20.	10% SDS disc gel of double-labelled brain supernatant of age-matched(47-day-old) 129Rej/dydy and 129Rej/?? mice	98
21.	10% SDS disc gel of double-labelled brain supernatant of age-matched(66-day-old) 129Rej/dydy and 129Rej/?? mice	100
22.	11.7% SDS disc gel of double-labelled brain mitochondrial fraction of age-matched(29-day-old) 129Rej/dydy and 129Rej/?? mice	103
23.	10% SDS disc gel of double-labelled brain mitochondrial fraction of age-matched(47-day-old) 129Rej/dydy and 129Rej/?? mice	105
24.	13% SDS disc gel of double-labelled brain mitochondrial fraction of age-matched(66-day-old) 129Rej/dydy and 129Rej/?? mice	107
25.	13% SDS disc gel of double-labelled spinal cord homogenate of age-matched(29-day-old) 129Rej/dydy and 129Rej/?? mice	109
26.	13% SDS disc gel of double-labelled spinal cord homogenate of age-matched(29-day-old) 129Rej/dydy and 129Rej/?? mice-tracking dye region omitted from calculations	111
27.	Semi-logarithmic plot with Log Molecular Weight($\times 10^{-3}$) versus the Relative Mobility(RM) of molecular weight standards for Type II and Type III gels	113
28.	13% SDS disc gel of double-labelled spinal cord homogenate of age-matched(47-day-old) 129Rej/dydy and 129Rej/?? mice	116
29.	13% SDS disc gel of double-labelled spinal cord homogenate (SDS-soluble fraction) of age-matched(66-day-old) 129Rej/dydy and 129Rej/?? mice	118
30.	13% SDS disc gel of double-labelled spinal cord homogenate of age-matched(66-day-old) 129Rej/dydy and 129Rej/?? mice	120
31.	13% SDS disc gel of free isotope both L-(U ¹⁴ C)leucine and L-(4,5 ³ H)leucine	122
32.	5.1% IEF gel of double-labelled spinal cord homogenate of age-matched(29-day-old) 129Rej/dydy and 129Rej/?? mice	128
33.	5.1% IEF gel of double-labelled spinal cord homogenate of age-matched(47-day-old) 129Rej/dydy and 129Rej/?? mice	130

34. 5.1% IEF gel of double-labelled spinal cord homogenate of age-matched(66-day-old) 129Rej/dydy and 129Rej/+? mice 132
35. Densitometric scans at 620nm of spinal cord homogenates of age-matched (A) 39-day-old (B) 44-day-old 129Rej/dydy and 129Rej/+? mice. 4.5% SDS-EDTA gels 138
36. Densitometric scans at 620nm of spinal root homogenates of age-matched (A) 44-day-old (B) 46-day-old 129Rej/dydy and 129Rej/+? mice. 13% SDS disc gels 141
37. Densitometric scans at 620nm of sciatic nerve homogenates of age-matched (A) 39,44 and 46-day-old normal(129Rej/+?) mice and (B) 39,44 and 46-day-old dystrophic(129Rej/dydy) mice. 13% SDS disc gels 144

LIST OF PICTURES

PICTURE

- | | |
|--|-----|
| I. Spinal cord homogenates(with spinal roots) of 129Rej/dydy and 129Rej/+? mice electrophoresed on 13% SDS disc gels | 135 |
| II. Spinal cord homogenates(without spinal roots) of 129Rej/dydy and 129Rej/+? mice electrophoresed on 13% SDS disc gels | 136 |
| III. Sciatic nerve homogenates of 129Rej/dydy and 129Rej/+? mice electrophoresed on 13% SDS disc gels | 142 |

LIST OF TABLES

TABLE

- I. Hamster Subcellular Fractions on Disc gel electrophoresis
Percentage Recovery of Label in Tracking Dye(T.D.) region

INTRODUCTION

The muscular dystrophies are a heterogeneous group of inherited diseases in man and animals. These diseases are characterized by striated muscle weakness and necrosis and usually lack any symptoms of nervous system disease (1). The progressive nature of these diseases is shown most dramatically in the human Duchenne muscular dystrophy. The disease heterogeneity is reflected in the different histological, electrophysiological and biochemical features of each type of muscular dystrophy as well as in their mode of inheritance. Any chance that these diseases have the same primary genetic(DNA) abnormality and biochemical expression of that abnormality at the cellular level is unlikely.

For many years the primary expression of this lesion was thought to occur in the muscle itself though the DNA carrying the muscular dystrophy mutation is contained in every cell (2). In recent times, however, the nervous system has been implicated in these diseases (3-16).

Why isn't the DNA abnormality studied directly, whether studying nervous tissue or striated muscles? The DNA lesion is difficult to study directly for two reasons. The first reason is the number and composition of gene loci present in each cell. In man there are between 40,000 and 100,000 structural gene loci (17). Each gene locus contains the nucleotide base sequence which is transcribed into its corresponding RNA and subsequently translated; resulting in a protein molecule(18). For every amino acid in the protein there is a corresponding triplet of nucleotide bases at the gene locus((19). This would mean that a small protein of 100 amino acids would be coded for by a base sequence of 300 nucleotide bases. The average length of a structural gene locus, however, is between 1000 and 1500 nucleotide base pairs (20). To study the number of bases involved at all the gene loci would be a formidable task.

The second reason there is a difficulty in studying DNA directly is that a point mutation, even a single base nucleotide substitution, can result in a grossly abnormal protein (19). These point mutations may result in changes in the charge(HbS in sickle cell anemia), in the molecular weight(haptoglobin variants), in the stability of a protein (glucose-6-phosphate-dehydrogenase variants), in the rate of synthesis of

of a protein or a complete failure of protein synthesis(thalasseмии) (19). Other mutations like crossing over on homologous chromosomes, or aberrant union after breaks in chromosomes occur, may result in duplication or deletion phenomena which bring about a change in the molecular weight of the protein (20). These mutations may alter the stability of the protein resulting in an altered half-life of the protein.

These various mutations, expressed in the amino acid sequence of a protein, may result in an abnormality which can be detected on the basis of altered molecular weight or altered charge of the protein. Differing rates of synthesis or degradation may also be detected in an analytical system which detects proteins quantitatively; such as polyacrylamide gel electrophoresis with sodium dodecyl sulphate(SDS-PAGE) or polyacrylamide gel electrofocusing(IEF gel).

The dual isotopic labelling technique is useful for studying genetically dystrophic and normal tissues. Dual labelling allows the simultaneous measurement of two different radioactive isotopes in the same sample. The isotopes can be distinguished on the basis of their half-lives or their energy spectrums, and therefore the amount of incorporated label present in a particular tissue or subcellular fraction can be determined. It is assumed that no biological discrimination occurs by the tissues in the utilization of the different isotopes of leucine.

In this study age-matched pairs of normal and dystrophic animals were injected with equimolar concentrations of a radioisotope of leucine (Figure 1). The tissues from the two animals were combined, homogenized and fractionated together therefore no anomalous differences related to differential sample preparation arise. This is an advantage of the dual labelling technique.

Because many thousand proteins exist in a single cell and the functions of only about 1300 are known (21) it may prove impotent to seek out specific cell proteins for analytical study. This would be especially true in genetic diseases where the disease origin is not known. Even when the 'basic defect' or abnormality is thought to be understood, unsuspected discoveries may show our limited knowledge and/or understanding of genetic diseases. In a recent study of cultured Pompe's fibroblasts where the




FIGURE 1. Flow scheme of the double isotopic labelling technique.

known basic genetic defect was a deficiency of α -1,4-glucosidase a second abnormality was found (22). This result was obtained using ^3H - and ^{14}C -leucine isotopes for labelling the Pompe's and normal fibroblasts in culture. The dual labelling technique has another advantage, then, in that it is unbiased.

This technique will be used to search for abnormal proteins of the nervous system tissues in the dystrophic hamster, strain BIO 14.6, and the murine dystrophy of Bar Harbour 129Rej/dydy mice.

HISTORICAL LITERATURE REVIEW

A. Muscular Dystrophy in Man and Animals

The muscular dystrophies are characterized by striated muscle weakness and necrosis. In the early phases of Duchenne muscular dystrophy (DMD) the patients' muscle appears to increase in mass. This is not due to an increase in muscle fibre material but to a replacement of the necrotic muscle cells by an excessive amount of fat tissue (1). Several histological changes in individual muscle fibre breakdown in DMD have been seen. These have been divided into five basic stages by Cullen and Fulthorpe (23). In Stage 1 the muscle fibres appear normal yet they have an increased volume in the sarcoplasm by 35-80%. A decrease in the mitochondrial volume also occurs. In transverse section the muscle fibres appear rounded rather than polyhedral in shape (23,24). In Stage 2 there is overcontraction of the myofibrils around the Z-line associated with overstretched regions in other parts of the sarcomere. Areas of overstretching are regions where no overlapping of the A and I bands occur. Z-line abnormalities occur and they are no longer at right angles to the longitudinal axis of the muscle fibre (23). Localized contraction continues in Stage 3 with the overstretched areas partly empty of the contractile myofibrils. The 'hyaline degeneration' characteristic of muscle fibres of DMD patients occurs in Stage 4. As the clumps of myofibrillar elements becomes more condensed retraction clots and retraction caps form. The final stage (Stage 5) occurs with the invasion of the muscle fibre by macrophages. Areas of hypercontraction have also been seen in Duchenne patients which show plasma membrane lesions (25).

Fatty infiltration (lipomatosis) also occurs in the muscle of these patients (26) along with the formation of fibrous tissue (27). An increase in the number of subsarcolemmal nuclei with 'nuclear rowing' is seen in the muscle fibres of patients with muscular dystrophy (24).

Several animals with an inherited muscular dystrophy show similar pathological characteristics to the Duchenne muscular dystrophy and have been used as models in the study of this disease. The hamster strain BIO 14.6 has a form of muscular dystrophy which involves the heart and skeletal muscle (28). The skeletal muscle shows the nuclear rowing and central localization of the nuclei, myolysis and macrophage infiltration and some fat accumulation in the muscle mass as is found in DMD (29). The mouse (murine) dystrophy, strain Bar Harbour 129Rej/dydy, also has these histological characteristics as well as nervous system abnormalities (14, 29, 30, 31).

These animal forms of dystrophy are inherited in an autosomal recessive pattern in contrast to that of the Duchenne muscular dystrophy inherited in an X-linked recessive pattern (1, 32, 33). Another animal model for muscular dystrophy, which has some similarities to the Duchenne muscular dystrophy, is that of the domestic chicken. This muscular dystrophy is co-dominantly inherited and affects mainly the fast (glycolytic) muscle fibres of the pectoral muscles of the chicken (34). The pectoralis muscle shows major phagocytic cell infiltration and fat replacement of the muscle mass as well as vacuolization of the muscle fibres (26, 35).

Though the animal forms of muscular dystrophy show similarities to DMD it is possible that the primary genetic lesion in these diseases is not the same. The study of muscular dystrophy in these animals may however

lead to an understanding of their particular biochemical abnormalities and thus the differences between dystrophic and normal animal tissue.

B. Evidence for Neurologic Involvement in Muscular Dystrophy

Because of the pathological characteristics of muscle in the muscular dystrophies they have been classified as myopathic diseases. A myopathy is usually defined as a disease with the primary disorder in the muscle (2). There are, however, several characteristics of muscle which are determined by the nerves which innervate them. The velocity of contraction and twitch duration can be altered by changing the nervous supply to the muscle (36). The enzyme and structural protein patterns of muscle can change as a result of a change in nervous stimulation; most specifically those proteins of the sarcoplasmic reticulum (37), myosin light chains in the contractile proteins (38,39) and enzymes involved in energy metabolism of muscle (40,41). The localization of acetylcholinesterase (AChE) activity to the muscle sole plate also does not occur without the nerve synapsing with the muscle fibre (42). The characteristics of muscle in DMD and those in denervated conditions or with altered neuronal influence often resemble each other in morphology, biochemistry, and electrophysiologically. One might have expected this to lead to the investigation of nervous system involvement in muscular dystrophy and even to the possibility that the dystrophy is neurogenic rather than myogenic in origin. However, it was not until in 1967, when McComas and Mrozek found defective motor innervation of the extensor digitorum brevis (EDB) muscle in the dystrophic mouse, strain 129Rej/dydy, and in 1970 when McComas found a reduction of the number of motor units in the EDB muscle in patients with DMD, that a neurogenic origin for muscular dystrophy